FDA Panel 7-2 Backs Grail's 50-Cancer Galleri Blood Test

For biotech and diagnostics developers, the FDA advisory panel's 7-2 endorsement of Grail's Galleri de-risks the first multi-cancer liquid biopsy, yet the committee's refusal to validate an early-detection claim signals that the next regulatory battles will center on labeling, post-approval studies, and reimbursement evidence.

On September 23, 2026, the FDA's Medical Devices Advisory Committee voted 7-2, with one abstention, to recommend that the agency approve Grail Inc.'s Galleri multi-cancer blood test for people aged 50 and older. The endorsement is the first time a federal advisory panel has backed an experimental multi-cancer early detection (MCED) blood test, potentially clearing a regulatory path for a technology that screens for up to 50 cancers from a single blood draw. Galleri does not diagnose cancer; it detects DNA methylation patterns in cell-free DNA that may signal the presence of a tumor, and a positive result requires follow-up diagnostic work. The test is already available by prescription at an out-of-pocket price of $949, but it is not yet FDA-authorized for broad screening, and insurance reimbursement is generally absent.

“

On September 23, 2026, the FDA's Medical Devices Advisory Committee voted 7-2, with one abstention, to recommend that the agency approve Grail Inc.'s Galleri multi-cancer blood test for people aged 50 and older.

The committee's decision was far from an unqualified victory for Grail. Earlier in the same meeting, panelists voted that the test appears safe and effective for the 50-plus population, but they declined to endorse the company's "early detection" claim. In Grail's two main large clinical trials, the test often failed to detect many cancers, especially early-stage tumors, which are the ones most likely to be curable with early intervention. Dr. Phil Castle, director of the National Cancer Institute's Division of Cancer Prevention, told the panel that the data on Galleri's performance were too premature to prove clinical benefit. He warned that "routine approval and broad population rollout would risk harm and waste resources." Dr. Victor van Berkel of UofL Physicians described his "yes" vote as "hopeful rather than an accurate one," explaining that the real benefit would come if the test finds early-stage cancers that are not currently screened for.

The broader context is that the U.S. has recommended screening programs for only a handful of tumor types—breast, colorectal, cervical, and lung among them—while most cancer deaths arise from cancers with no routine screening. MCED tests like Galleri have promised to close that gap by detecting multiple cancer signals in asymptomatic people. The public-health argument is especially compelling for rural and underserved populations with limited access to colonoscopy or imaging. Grail insists Galleri should be additive to standard screenings such as mammograms and colonoscopies, not a replacement, but the panel's warnings about false reassurance cut to the heart of the clinical uncertainty. A negative test could lead patients to skip standard screenings, while a positive test could trigger a cascade of imaging, biopsies, and specialist visits with uncertain benefit and real costs.